BIOTECHNOLOGICAL PRODUCTION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR PROTEIN & ITS APPLICATION

Biopharmaceuticals based on proteins, antibodies or nucleic acids are progressively used for the treatment of various diseases. This review discusses Tissue plasminogen activator (tPA or PLAT) as a biopharmaceuticals product, its synthesis, and administration of disease. Tissue plasminogen activator is a serine protease. It plays the role of conversion of plasminogen to plasmin. It is the major enzyme, responsible for the breakdown of the clot. In order to fulfill the acute demand of this product in the market, one of the premier methods is the biotechnological production of recombinant tissue plasminogen activator protein (reteplase) by transplastomic tobacco cell cultures. Other methods of production include, Human Tissue Plasminogen Activator (t-PA) c-DNA active expression from Pulmonary Metastases in the Methylotrophic Yeast Pichia PastorisKM71H, Strain and expression of Human Tissue Plasminogen, Activator in Escherichia coli using cytoplasmic and periplasmic cumulative Power. These methods describe the various aspects related to tPA, and have potential ability to produce tissue plasminogen activator protein.